LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

#5

Atty. Docket No.	Serial No.
6309.NCP	09/826,461
Applicant: RL Heinrikson, MJ Bienkowski	
Filing Date: April 17, 2001	Group: 1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
mmm	AA	4,373,023	Feb. 8, 1983	RS Langer, R Linhardt, CL Cooney, PM Galliher, MM Flanagan, MD Klein	A01N	1/02	Oct. 14, 1980
	AB	4,863,611	Sep. 5, 1989	H Bernstein, MA Wheatley, RS Langer	B01D	15/02	Apr. 30, 1987
	AC	5,211,850	May 18, 1993	U Shettigar, JC McRea,	B01D	61/00	Jul. 26, 1991
mmm	AD	5,567,417	Oct. 22, 1996	R Sasisekharan, MA Moses, MA Nugent, CL Cooney, RS Langer	A61K	38/51	May 1, 1995

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
mmm	AE	WO 91/02977	Mar. 7, 1991	World	G01N	33/53	X	
	AF	WO 91/09955	July 11, 1991	World	C12N	15/67	X	
	AG	WO 91/18982	Dec. 12, 1991	World	C12N	15/12	X	
	AH	WO 92/20808	Nov. 26, 1992	World	C12N	15/85	X	
	AI	WO 93/11236	June 10, 1993	World	C12N	15/13	X	
	AJ	WO 94/12650	June 9, 1994	World	C12N	15/90	X	
	AK	WO 97/09433	Mar. 13, 1997	World	C12N	15/54	X	
	AL	WO 97/11684	Apr. 3, 1997	World	A61K	9/14	X	
	AM	WO 98/03638	Jan. 29, 1998	World	C12N	9/24	X	
mmm	AN	EP 0367566	Oct. 31, 1989	Europe	C12N	15/12	X	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	~~Adv. Appl. Math. 2: 482-489 (1981)~~
mmm	AP	Anderson, W.F., *Human gene therapy*. Nature, 1998. **392**(6679 Suppl): p. 25-30
	AQ	Aujame, L., F. Geoffroy, and R. Sodoyer, *High affinity human antibodies by phage display*. Hum Antibodies, 1997. **8**(4): p. 155-68
	AR	Ausubel, *et al.*, ed., in Short Protocols in Molecular Biology, 2nd edition, John Wiley & Sons, publishers, pg. 16-49, 1992
mmm	AS	Ausubel, et al. (Eds.), Protocols in Molecular Biology, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10

Form 1449
1/92-ka

LIST OF REFERENCES CITED BY APPLICANT *(Use several sheets if necessary)*	Atty. Docket No. 6309.NCP	Serial No. 09/836,461
	Applicant RL Heinrikson, MJ Bienkowski	
	Filing Date April 17, 2001	Group 1646

	AT	~~Biochemistry, Second Edition, Worth Publishrs, Inc. NY:NY (1975), pp. 71-77~~
mm	AU	Bruggemann, M. and M.S. Neuberger, *Strategies for expressing human antibody repertoires in transgenic mice.* Immunol Today, 1996. **17**(8): p. 391-7
	AV	Bruggemann, M. and M.J. Taussig, *Production of human antibody repertoires in transgenic mice.* Curr Opin Biotechnol, 1997. **8**(4): p. 455-8
	AW	Capecchi, M.R., *Altering the genome by homologous recombination.* Science, 1989. **244**(4910): p. 1288-92
	AX	Choo, Y., *et al.*, *Promoter-specific activation of gene expression directed by bacteriophage-selected zinc fingers.* J Mol Biol, 1997. **273**(3): p. 525-32
	AY	Cosman, D., *et al.*, *Cloning, sequence and expression of human interleukin-2 receptor.* Nature, 1984. **312**(5996): p. 768-71
	AZ	Cosman, D., *et al.*, *High level stable expression of human interleukin-2 receptors in mouse cells generates only low affinity interleukin-2 binding sites.* Mol Immunol, 1986. **23**(9): p. 935-41
	BA	Dayhoff, in *Atlas of Protein Sequence and Structure*, Vol. 5, p. 124, National Biochemical Research Foundation, Washington, D.C. (1972)
	BB	Erlich H. A., ed., *PCR Technology*, Stockton Press, New York, 1989;
	BC	Foote, J. and G. Winter, *Antibody framework residues affecting the conformation of the hypervariable loops.* J Mol Biol, 1992. **224**(2): p. 487-99.
	BD	Friedman, Science, 244: 1275-1281 (1989)
	BE	Gluzman, Y., *SV40-transformed simian cells support the replication of early SV40 mutants.* Cell, 1981. **23**(1): p. 175-82.
	BF	Godder, K., *et al.*, *Heparanase activity in cultured endothelial cells.* J Cell Physiol, 1991. **148**(2): p. 274-80.
	BG	Greisman, H.A. and C.O. Pabo, *A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites.* Science, 1997. **275**(5300): p. 657-61
	BH	Haimovitz-Friedman, A., *et al.*, *Activation of platelet heparitinase by tumor cell-derived factors.* Blood, 1991. **78**(3): p. 789-96
	BI	Harlow et al. (Eds), *Antibodies A Laboratory Manual;* Cold Spring Harbor Laboratory; Cold Spring Harbor , NY (1988), Chapter 6
	BJ	Fairbanks MB *et al. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer.* 1999 Journal of Biological Chemistry. 274(42):29587-90
	BK	Hoogenboom, HR Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol, 1997. 15(2): p. 62-70
	BL	Hoogewerf, A.J., *et al.*, *CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes.* J Biol Chem, 1995. **270**(7): p. 3268-77.
	BM	Hopp, T.P. and K.R. Woods, *A computer program for predicting protein antigenic determinants.* Mol Immunol, 1983. **20**(4): p. 483-9
mm	BN	Hopp, T.P. and K.R. Woods, *Prediction of protein antigenic determinants from amino acid sequences.* Proc Natl Acad Sci U S A, 1981. **78**(6): p. 3824-8.

Form 1449
1/92-ka

LIST OF REFERENCES CITED BY APPLICANT *(Use several sheets if necessary)*	Atty. Docket No. 6309.NCP	Serial No. 09/836,231
	Applicant RL Heinrikson, MJ Bienkowski	
	Filing Date April 17, 2001	Group 1646

	BO	Hulett, M.D., *et al.*, *Cloning and expression of human and murine heparanase, an important enzyme in tumor invasion and metastasis.* Nature Genetics, 1999 5:803-809
	BP	Innis M. A., *et al.* eds *PCR Protocols: A Guide to Methods and Applications* 1990, Academic Press, Inc., New York
	BQ	Jones, P.T., *et al.*, *Replacing the complementarity-determining regions in a human antibody with those from a mouse.* Nature, 1986. **321**(6069): p. 522-5
	BR	Kettleborough, C.A., *et al.*, *Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.* Protein Eng, 1991. **4**(7): p. 773-83.
	BS	Khan, M.Y. and S.A. Newman, *A rapid colorimetric assay for heparinase activity.* Anal Biochem, 1991. **196**(2): p. 373-6
	BT	Kim, J.S., *et al.*, *Design of TATA box-binding protein/zinc finger fusions for targeted regulation of gene expression.* Proc Natl Acad Sci U S A, 1997. **94**(8): p. 3616-20.
	BU	Klein, U. and K. Von Figura, *Partial purification and characterization of heparan sulfate specific endoglucuronidase.* Biochem Biophys Res Commun, 1976. **73**(3): p. 569-76
	BV	Kosir, M.A., *et al.*, *Human prostate carcinoma cells produce extracellular heparanase.* J Surg Res, 1997. **67**(1): p. 98-105
	BW	Kussie, P.H. *et al. Cloning and Functional Expression of a Human Heparanase Gene* , Biochem. Biophys. Res. Comm. 1999 261:183-187
	BX	Langer et al. *Biomaterials: Inter-facial Phenomenon and Applications*, Cooper *et al.*, eds., pp. 493-509 (1982)
	BY	Lehninger, *Biochemistry*, Second Edition; Worth Publishers, Inc. NY:NY (1975), pp.71-77
	BZ	Liu, Q., *et al.*, *Design of polydactyl zinc-finger proteins for unique addressing within complex genomes.* Proc Natl Acad Sci U S A, 1997. **94**(11): p. 5525-30
	CA	Luckow and Summers, *Bio/Technology* 6:47 (1988)
	CB	Margalit, H., *et al.*, *Prediction of immunodominant helper T cell antigenic sites from the primary sequence.* J Immunol, 1987. **138**(7): p. 2213-29
	CC	Matzner, Y., *et al.*, *Subcellular localization of heparanase in human neutrophils.* J Leukoc Biol, 1992. **51**(6): p. 519-24.
	CD	McColl, D.J., C.D. Honchell, and A.D. Frankel, *Structure-based design of an RNA-binding zinc finger.* Proc Natl Acad Sci U S A, 1999. **96**(17): p. 9521-6.
	CE	Miller, A.D., *Human gene therapy comes of age.* Nature, 1992. **357**(6378): p. 455-60.
	CF	Morrison and Oi, Adv. Immunol., 44: 65-92 (1989)
	CG	Nakajima *et al.* Anal. Biochem. 196: 162-171, 1986
	CH	Nakajima, M., T. Irimura, and G.L. Nicolson, *Tumor metastasis-associated heparanase (heparan sulfate endoglycosidase) activity in human melanoma cells.* Cancer Lett, 1986. **31**(3): p. 277-83.
	CI	Ogren, S. and U. Lindahl, *Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma.* J Biol Chem, 1975. **250**(7): p. 2690-7

LIST OF REFERENCES CITED BY APPLICANT *(Use several sheets if necessary)*	Atty. Docket No. 6309.NCP	Serial No. 09/836,461
	Applicant RL Heinrikson, MJ Bienkowski	
	Filing Date April 17, 2001	Group 1646

mmm		Okayama, H. and P. Berg, *A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells.* Mol Cell Biol, 1983. **3**(2): p. 280-9
	CK	Padlan, Molecular Immunol., 28(4/5):489-98 (1991)
	CL	Parish, C.R., *et al.*, *Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases.* Int J Cancer, 1987. **40**(4): p. 511-8
	CM	Rader, C. and C.F. Barbas, 3rd, *Phage display of combinatorial antibody libraries.* Curr Opin Biotechnol, 1997. **8**(4): p. 503-8
	CN	Rapraeger, A.C., A. Krufka, and B.B. Olwin, *Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.* Science, 1991. **252**(5013): p. 1705-8
	CO	Riechmann, L., *et al.*, *Reshaping human antibodies for therapy.* Nature, 1988. **332**(6162): p. 323-7.
	CP	Sambrook, *et al.*, (Eds.), *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989), pp. 9.47 to 9.51
	CQ	Savion, N., M.H. Disatnik, and Z. Nevo, *Murine macrophage heparanase. inhibition and comparison with metastatic tumor cells.* J Cell Physiol, 1987. **130**(1): p. 77-84.
	CR	Segal, D.J., *et al.*, *Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences.* Proc Natl Acad Sci U S A, 1999. **96**(6): p. 2758-63
	CS	Sewell, R.F., P.E. Brenchley, and N.P. Mallick, *Human mononuclear cells contain an endoglycosidase specific for heparan sulphate glycosaminoglycan demonstrable with the use of a specific solid-phase metabolically radiolabelled substrate.* Biochem J, 1989. **264**(3): p. 777-83
	CT	Shively, J.E. and H.E. Conrad, *Formation of anhydrosugars in the chemical depolymerization of heparin.* Biochemistry, 1976. **15**(18): p. 3932-42
	CU	Tempest, P.R., *et al.*, *Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo.* Biotechnology (N Y), 1991. **9**(3): p. 266-71
	CV	Toyoshima, M. *et al. Human heparanase: Purification, characterization, cloning and expression.* J. Biol. Chem. **274**:29587-29590
	CW	Verhoeyen, M., C. Milstein, and G. Winter, *Reshaping human antibodies: grafting an antilysozyme activity.* Science, 1988. **239**(4847): p. 1534-6
	CX	Verma, I.M., *Gene therapy.* Sci Am, 1990. **263**(5): p. 68-72, 81-4
	CY	Vettel, U., *et al.*, *Coordinate secretion and functional synergism of T cell-associated serine proteinase-1 (MTSP-1) and endoglycosidase(s) of activated T cells.* Eur J Immunol, 1991. **21**(9): p. 2247-51
	CZ	Van Regenmortel, M.H.V., 1986. *Trends in Biological Sciences* 11: 36-39.
	DA	Vlodavsky, I., et al., Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis, 1992. **12**(2): p. 112-27.
mmm	DB	Vlodavsky I. et al., Mammalian *heparanase*: gene cloning, expression and function in tumor progression and metastasis.,

LIST OF REFERENCES CITED BY APPLICANT *(Use several sheets if necessary)*	Atty. Docket No. 6309.NCP	Serial No. 09/836,461
	Applicant RL Heinrikson, MJ Bienkowski	
	Filing Date April 17, 2001	Group 1646

		1999 Nature Medicine. **5**(7):793-802
	DC	Wu, H., W.P. Yang, and C.F. Barbas, 3rd, *Building zinc fingers by selection: toward a therapeutic application.* Proc Natl Acad Sci U S A, 1995. **92**(2): p. 344-8
mmm	DD	Yahalom, J., *et al.*, *Differentiating human leukemia cells express heparanase that degrades heparan sulfate in subendothelial extracellular matrix.* Leuk Res, 1988. **12**(9): p. 711-7
Examiner mmm		Date Considered 5/19/03

Form 1449
1/92-ka